RebrAIn
RebrAIn makes it possible for individuals with severe Parkinson's or essential tremor disorder to get DBS treatment with precision targeting. Neurosurgeons can more accurately pinpoint the target location for electrode surgical insertion with the use of this SaaS service. Its innovative method predicts the treatment zone in each patient's brain using machine learning clinical patient data.
RebrAIn
RebrAIn makes it possible for individuals with severe Parkinson's or essential tremor disorder to get DBS treatment with precision targeting. Neurosurgeons can more accurately pinpoint the target location for electrode surgical insertion with the use of this SaaS service. Its innovative method predicts the treatment zone in each patient's brain using machine learning clinical patient data.
TL;DR
What they do: AI-driven millimetric MRI-guided targeting software/services for stereotactic neurosurgery (DBS and lesioning)
Regulatory status: CE marked and FDA 510(k) cleared software
Traction: Deployed at over 55 sites with 500+ targeting operations
Recent funding: Seed round announced Mar 18, 2024 (~€3.7M / $4.02M)
Company Overview
Problem Domain
Stereotactic neurosurgery for movement disorders (Parkinson's disease, essential tremor)
Industry
Medical device / MedTech
Funding Track Record
€3.7 million
Participating investors include NACO and Nouvelle Aquitaine Co-Investissement; reported amount in euros.
Investor Signal
“VC participation led by Karista with regional co-investor support (Nouvelle Aquitaine Co-Investissement) and participation from NACO”